Wednesday, February 28

Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by PDT Partners LLC



PDT Partners LLC lessened its position in Inari Medical, Inc. (NASDAQ:NARI – Get Rating) by 14.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 43,760 shares of the company’s stock after selling 7,691 shares during the period. PDT Partners LLC owned approximately 0.08% of Inari Medical worth $3,966,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in NARI. Advisor Group Holdings Inc. lifted its stake in shares of Inari Medical by 43.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 1,683 shares of the company’s stock worth $153,000 after acquiring an additional 508 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Inari Medical by 10.3% in the 4th quarter. Victory Capital Management Inc. now owns 5,041 shares of the company’s stock worth $460,000 after acquiring an additional 472 shares during the period. Bank of America Corp DE lifted its stake in shares of Inari Medical by 4.0% in the 4th quarter. Bank of America Corp DE now owns 101,868 shares of the company’s stock worth $9,297,000 after acquiring an additional 3,918 shares during the period. First Republic Investment Management Inc. purchased a new position in shares of Inari Medical in the 4th quarter valued at about $255,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Inari Medical by 88.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 222,218 shares of the company’s stock valued at $20,282,000 after purchasing an additional 104,266 shares in the last quarter. Institutional investors and hedge funds own 84.11% of the company’s stock.

Also Read  High temperatures from heat dome break records

Insiders Place Their Bets

In other Inari Medical news, CEO William Hoffman sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $71.99, for a total transaction of $2,159,700.00. Following the sale, the chief executive officer now directly owns 548,899 shares of the company’s stock, valued at approximately $39,515,239.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Inari Medical news, CEO William Hoffman sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $71.99, for a total transaction of $2,159,700.00. Following the sale, the chief executive officer now directly owns 548,899 shares of the company’s stock, valued at approximately $39,515,239.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Andrew Hykes sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $70.31, for a total transaction of $351,550.00. Following the sale, the chief operating officer now directly owns 140,991 shares in the company, valued at $9,913,077.21. The disclosure for this sale can be found here. Insiders have sold 142,012 shares of company stock valued at $10,514,940 in the last ninety days. Insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NARI. BTIG Research cut their price target on shares of Inari Medical from $130.00 to $100.00 and set a “buy” rating for the company in a report on Friday, June 24th. Piper Sandler began coverage on shares of Inari Medical in a report on Tuesday, June 21st. They issued an “overweight” rating and a $100.00 price target for the company. Finally, Morgan Stanley cut their price target on shares of Inari Medical from $108.00 to $93.00 and set an “overweight” rating for the company in a report on Friday, July 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Inari Medical presently has an average rating of “Buy” and a consensus target price of $96.67.

Also Read  Jan. 6 panel zeroes in on Trump tweet- POLITICO

Inari Medical Stock Performance

NASDAQ:NARI opened at $77.27 on Monday. The firm has a 50-day moving average price of $75.08 and a two-hundred day moving average price of $75.96. Inari Medical, Inc. has a twelve month low of $50.50 and a twelve month high of $100.00.

Inari Medical (NASDAQ:NARI – Get Rating) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.04. Inari Medical had a negative net margin of 4.47% and a negative return on equity of 4.60%. The firm had revenue of $92.74 million during the quarter, compared to the consensus estimate of $88.04 million. On average, equities analysts anticipate that Inari Medical, Inc. will post -0.66 earnings per share for the current year.

About Inari Medical

(GetRating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and Flow Triever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Featured Articles

Institutional Ownership by Quarter for Inari Medical (NASDAQ:NARI)



Receive News & Ratings for Inari Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inari Medical and related companies with MarketBeat.com’s FREE daily email newsletter.

Also Read  Sunday, Monday rain might help suppress flames


reporter.am

Leave a Reply

Your email address will not be published. Required fields are marked *